The Industrial Development Fund (IDF) has approved a preferential loan of 945 million rubles for Alsigma company (part of Altegra JSC). The funds will be directed towards purchasing equipment for a research and production complex that the company is creating within the Dubna SEZ. The total investment in the project, which has been under implementation since 2025, is estimated at 1.5 billion rubles.
The IDF support will allow the facility to be equipped with high-tech lines for the production of import-substituting medicines, including hormonal anti-cancer drugs and generics.
Scaling Production
Ekaterina Zinovieva, Deputy Chairman of the Government – Minister of Investment, Industry and Science of the Moscow Region, noted the significance of federal support for the development of regional projects:
“The total investment volume in the implementation of Alsigma’s large-scale project is estimated at 1.5 billion rubles. Of this amount, the company received 945 million rubles in the form of a preferential loan from the federal IDF. It is planned to create 60 jobs at the enterprise.”
Transition to Own Capacities
Olga Turchaninova, General Director of Alsigma LLC, emphasized that the financing will accelerate the transition from rented areas to the company’s own production. Previously, production was carried out at the Mendeleev Innovation and Technology Center; now, the company is building an independent plant.
“Now we are 100% founders of our subsidiary Alsigma, and we have the opportunity to build our own complex. With preferential financing from the IDF, we can even more actively implement our common goals for the import substitution of medicines,” stated Olga Turchaninova.
Parameters and Launch Deadlines
The construction of the complex, with a total area of 7.4 thousand square meters, is being carried out in stages. According to Anton Afanasyev, General Director of SEZ TVT Dubna JSC, the launch of the first phase (a production building of 5.3 thousand square meters) is scheduled for the second quarter of 2027.
Full commissioning is planned for 2029. The plant’s design capacity will be 140 million product units per year (tablets, capsules, sterile forms), and a warehouse terminal for 1,100 pallet spaces is also provided.
